---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-089676"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2022-08-12T23:59:59+00:00"
generated_at: "2026-06-24T00:19:29.443417+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics reports Q2 net loss $17M, cash $90.9M; director Bertagnolli resigns for NCI role

## Summary
- Net loss $17.0M in Q2 2022 ($9.5M in Q2 2021); R&D expenses $14.0M vs $7.2M, driven by manufacturing and trial costs.
- Cash and equivalents $90.9M at June 30, 2022, providing expected runway into mid-2024.
- Initiated Part C of DisTinGuish study (DKN-01 + tislelizumab + chemo) in first-line G/GEJ cancer; also started DeFiance study in second-line CRC.
- Director Dr. Monica Bertagnolli resigned effective Aug 12, 2022 to become Director of the National Cancer Institute; no disagreement with company.
- Presented initial prostate cancer data at ASCO 2022: in combination cohort, all 6 patients had >50% PSA reduction, 5 with measurable disease had partial response.

## SEC filing metadata
- accession: 0001104659-22-089676
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2022-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/0001104659-22-089676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/tm2223284d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-089676
- JSON: https://secwatch.observer/filing/0001104659-22-089676.json
- Plain text: https://secwatch.observer/filing/0001104659-22-089676.txt

## Key facts
- Executive change
  Monica Bertagnolli resigned as director at CYPHERPUNK TECHNOLOGIES INC..
  - Action: resigned
  - Role: director
  source text: On August 11, 2022, Dr. Monica Bertagnolli, a director of the Company, informed the Company that she will be resigning as a director, effective August 12, 2022, as a result of her appointment as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465922089676/0001104659-22-089676-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.